| Company Name: |
LGM Pharma |
| Tel: |
1-(800)-881-8210 |
| Email: |
inquiries@lgmpharma.com |
| Company Name: |
BOC Sciences |
| Tel: |
16314854226; +8616314854226 |
| Email: |
inquiry@bocsci.com |
|
| | DIAZIQUONE Basic information |
| Product Name: | DIAZIQUONE | | Synonyms: | aziridinylbenzoquinone;aziridinylquinone;azq;diaziquone;nsc182986;AZQ, 2,5-Bis(1-aziridinyl)-3,6-bis-(carbethoxyamino)-1,4-benzoquinone;Diaziquon;NSC-182896 | | CAS: | 57998-68-2 | | MF: | C16H20N4O6 | | MW: | 364.35 | | EINECS: | | | Product Categories: | | | Mol File: | 57998-68-2.mol |  |
| | DIAZIQUONE Chemical Properties |
| Melting point | 230° (dec) | | Boiling point | 495.56°C (rough estimate) | | density | 1.2204 (rough estimate) | | refractive index | 1.6000 (estimate) | | form | Solid | | color | Orange needles from EtOH |
| Hazard Codes | Xn | | Risk Statements | 40 | | Safety Statements | 22-36 | | RTECS | EY8794000 | | Toxicity | LD50 in mice (mg/m2): 30.9 i.v. (Bender) |
| | DIAZIQUONE Usage And Synthesis |
| Uses | Antineoplastic. | | Definition | ChEBI: A 1,4-benzoquinone that is substituted at positions 2 and 5 have been replaced by aziridin-1-yl groups and at positions 3 and 6 by (ethoxycarbonyl)amino groups. | | Safety Profile | Poison by intravenous andintraperitoneal routes. Human mutation data reported.When heated to decomposition it emits toxic fumes ofNOx. | | in vivo | Diaziquone (6.75mg /sq m daily for 5 consecutive days or single-dose 26 mg/sq m) has a broad range of activity of diaziquone against primary nervous system tumors and has enhancement effect combined with either 1,3-bis(2-chloroethyl)-1-nitrosourea or procarbazine in athymic mice[1]. | Animal Model: | Homozygous nu/nu BALB/c athymic mice[1] | | Dosage: | 6.75mg /sq m or 26 mg/sq m | | Administration: | 6.75mg /sq m daily for 5 consecutive days or single-dose 26 mg/sq m | | Result: | Showed rapid clearance in the plasma of athymic mice with a half-life of approximately 11.5 min.
Produced significant growth delays.
Produced significant increases in the median growth delay, significant increases in the number of tumor regressions.
|
|
| | DIAZIQUONE Preparation Products And Raw materials |
|